C. la Fougère
University of Tübingen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by C. la Fougère.
Molecular Imaging and Biology | 2015
Dale L. Bailey; Bernd J. Pichler; Brigitte Gückel; Henryk Barthel; A. J. Beer; J. Bremerich; Johannes Czernin; Alexander Drzezga; Christiane Franzius; Vicky Goh; Markus Hartenbach; H. Iida; Andreas Kjær; C. la Fougère; C. N. Ladefoged; Ian Law; K Nikolaou; Harald H. Quick; Osama Sabri; Jürgen F. Schäfer; Michael Schäfers; Thomas Beyer
This paper summarises key themes and discussions from the 4th international workshop dedicated to the advancement of the technical, scientific and clinical applications of combined positron emission tomography (PET)/magnetic resonance imaging (MRI) systems that was held in Tübingen, Germany, from February 23 to 27, 2015. Specifically, we summarise the three days of invited presentations from active researchers in this and associated fields augmented by round table discussions and dialogue boards with specific topics. These include the use of PET/MRI in cardiovascular disease, paediatrics, oncology, neurology and multi-parametric imaging, the latter of which was suggested as a key promoting factor for the wider adoption of integrated PET/MRI. Discussions throughout the workshop and a poll taken on the final day demonstrated that attendees felt more strongly that PET/MRI has further advanced in both technical versatility and acceptance by clinical and research-driven users from the status quo of last year. Still, with only minimal evidence of progress made in exploiting the true complementary nature of the PET and MRI-based information, PET/MRI is still yet to achieve its potential. In that regard, the conclusion of last year’s meeting “the real work has just started” still holds true.
Molecular Imaging and Biology | 2016
Dale L. Bailey; Bernd J. Pichler; Brigitte Gückel; Henryk Barthel; Ambros J. Beer; René M. Botnar; Robert J. Gillies; Vicky Goh; Martin Gotthardt; Rodney J. Hicks; Rupert Lanzenberger; C. la Fougère; M. Lentschig; Stephan G. Nekolla; T. Niederdraenk; K Nikolaou; Johan Nuyts; D. Olego; K. Åhlström Riklund; Alberto Signore; Michael Schäfers; Vesna Sossi; M. Suminski; Patrick Veit-Haibach; L. Umutlu; M. Wissmeyer; Thomas Beyer
This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.
Molecular Imaging and Biology | 2018
Dale L. Bailey; Bernd J. Pichler; Brigitte Gückel; Gerald Antoch; Henryk Barthel; Z. M. Bhujwalla; Saskia Biskup; Sandip Biswal; M. Bitzer; Ronald Boellaard; R. F. Braren; Cornelia Brendle; Kevin M. Brindle; Arturo Chiti; C. la Fougère; Robert J. Gillies; Vicky Goh; M. Goyen; Marcus Hacker; L. Heukamp; Gitte M. Knudsen; A. M. Krackhardt; Ian Law; John C. Morris; Konstantin Nikolaou; Johan Nuyts; Alvaro A. Ordonez; K. Pantel; Harald H. Quick; Katrine Riklund
The 6th annual meeting to address key issues in positron emission tomography (PET)/magnetic resonance imaging (MRI) was held again in Tübingen, Germany, from March 27 to 29, 2017. Over three days of invited plenary lectures, round table discussions and dialogue board deliberations, participants critically assessed the current state of PET/MRI, both clinically and as a research tool, and attempted to chart future directions. The meeting addressed the use of PET/MRI and workflows in oncology, neurosciences, infection, inflammation and chronic pain syndromes, as well as deeper discussions about how best to characterise the tumour microenvironment, optimise the complementary information available from PET and MRI, and how advanced data mining and bioinformatics, as well as information from liquid biomarkers (circulating tumour cells and nucleic acids) and pathology, can be integrated to give a more complete characterisation of disease phenotype. Some issues that have dominated previous meetings, such as the accuracy of MR-based attenuation correction (AC) of the PET scan, were finally put to rest as having been adequately addressed for the majority of clinical situations. Likewise, the ability to standardise PET systems for use in multicentre trials was confirmed, thus removing a perceived barrier to larger clinical imaging trials. The meeting openly questioned whether PET/MRI should, in all cases, be used as a whole-body imaging modality or whether in many circumstances it would best be employed to give an in-depth study of previously identified disease in a single organ or region. The meeting concluded that there is still much work to be done in the integration of data from different fields and in developing a common language for all stakeholders involved. In addition, the participants advocated joint training and education for individuals who engage in routine PET/MRI. It was agreed that PET/MRI can enhance our understanding of normal and disrupted biology, and we are in a position to describe the in vivo nature of disease processes, metabolism, evolution of cancer and the monitoring of response to pharmacological interventions and therapies. As such, PET/MRI is a key to advancing medicine and patient care.
Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren | 2016
Sergios Gatidis; C. la Fougère; J. F. Schaefer
UNLABELLED Pediatric imaging has been identified as a key application of combined whole-body PET/MRI. First studies have revealed the clinical feasibility and possible advantages of PET/MRI over PET/CT and MRI. Besides a significant reduction in radiation exposure of about 50 - 75 %, combined whole-body PET/MRI offers the diagnostic advantage of the multiparametric characterization of pathophysiologic processes and helps reduce the number of necessary imaging studies. However, very few studies focusing on pediatric PET/MRI have been published to date. Additional studies are necessary in order to fully appreciate the clinical impact of this novel method. This review article shall summarize the existing literature concerning pediatric PET/MRI and give insight into the practical experience derived from over 160 pediatric PET/MRI examinations that were performed in Tübingen. KEY POINTS •Combined PET/MR is a promising imaging modality in pediatric oncology. •Using combined PET/MRI, diagnostic radiation exposure of pediatric patients and the number of necessary imaging studies can be reduced. •Further clinical studies are necessary in order to define specific indications for combined PET/MRI in pediatric radiology.
European Neuropsychopharmacology | 2015
Axel Rominger; Paul Cumming; Matthias Brendel; Guoming Xiong; Christian Zach; S. Karch; Klaus Tatsch; Peter Bartenstein; C. la Fougère; Walter Koch; Oliver Pogarell
Altered SERT and DAT availabilities during treatment with escitalopram were investigated with [(123)I]2β-carbomethoxy-3β-(4-iodophenyl)tropane (β-CIT) SPECT in a series of patients fulfilling the criteria for unipolar major depressive disorder (MDD). 27 patients (10m, 42±16y) with diagnosis of MDD were recruited for the study. All patients underwent neuropsychiatric testing for assessment of Hamilton Depression (HAM-D) and Beck Depression Inventory (BDI) scores. At baseline, [(123)I]β-CIT SPECT recordings were acquired 4h (SERT-weighted) and 20-24h p.i (DAT-weighted). Follow-up scans and neuropsychiatric testing were performed after six weeks of stable escitalopram medication. Voxel-wise parametric maps of specific/ non-specific ratios-1 (~BPND) were calculated. At baseline, DAT-weighted BPND was 5.06±0.81 in striatum and SERT-weighted BPND was 0.94±0.18 in thalamus. There were significant negative correlations with age for DAT in striatum (R=-0.60; p<0.01) and SERT in thalamus (R=-0.45; p<0.05). Under SSRI treatment there was an apparent 42% occupancy of SERT in thalamus (p<0.0001), whereas DAT availability increased significantly by 20% in striatum (p<0.001); higher apparent SERT occupancy in thalamus was associated with lesser DAT increase in striatum (R=-0.62; p<0.005). The low apparent SERT occupancy may be confounded by alterations in SERT expression during treatment. Thus, [(123)I]β-CIT SPECT revealed age-dependent declines in DAT and SERT availabilities in un-medicated MDD patients, comparable to that seen previously in healthy controls. At follow-up, the SSRI-evoked increase in DAT was less pronounced in the older patients, even though apparent SERT occupancy and clinical improvement were not age-dependent. Present findings may have implications for escitalopram dosage and side effect profile in younger MDD patients.
European Journal of Radiology | 2016
Gerd Grözinger; Jürgen Kupferschläger; Helmut Dittmann; M. Maurer; Ulrich Grosse; C. la Fougère; Konstantin Nikolaou; Roland Syha; Dominik Ketelsen
PURPOSE Aim of the study was to evaluate the impact of parenchymal blood volume (PBV) C-arm CT in transarterial radioembolization (TARE) planning procedure regarding the appropriateness of segmental blood supply from selective catheter positions defined by angiographic images compared to PBV mapsto determine the influence of changed target volumes on dose calculation. MATERIAL AND METHODS A total of 22 consecutive patients (median age, 62 years) underwent a TARE planning procedure were included in this retrospective study. Selective angiograms and selective PBV C-arm CT (right and left liver lobe) were evaluated in a blinded fashion, regarding segmental hepatic artery variants. Volumetry of target volume and dosimetry of glass and resin microspheres were performed. RESULTS Classification of segment IV and segment I to the corresponding target vascular bed supply was correct in 91.0% (20/22) and 86.4% (19/22) for angiography and C-arm CT, respectively. Except one case, all other liver segments were classified properly to the left and right hepatic arterial supply. Based on the mismatch of the angiographic and the C-arm CT approach, changes of target volume were evident in 27.3% of patients, resulting in a mean mismatch volume of 90±54ml (range, 51-198ml) and a percentage of dose differences of 14.2±11.8% and 12.6±10.6% for the right and 12.5±8.5% and 11.1±7.8% for the left liver lobe in glass and resin microspheres, respectively. CONCLUSION The C-arm CT approach is superior to the angiographic determination of vascular supply of specific liver segments for dosimetry before radioembolization. Especially for unexperienced interventional radiologists or for a complex anatomy, C-arm CT improves individualized dosimetry concepts.
Clinical Neurophysiology | 2007
G. Schmitt; C. la Fougère; S. Dresel; Thomas Frodl; Klaus Hahn; H.-J. Möller; E. M. Meisenzahl
Introduction: In a recently introduced mathematical model ICP was assessed non-invasively (nICP) by usage of arterial blood pressure (ABP) and cerebral blood flow velocity (FV) curves. Well-defined haemodynamic parameters (TCD characteristics) derived from both signals, were taken to control a linear signal transformation of ABP into ICP. In the current work attempts were made to improve former results by application of advanced data analysis techniques. Methods: In 201 patients (3–78 years, mean: 37 ± 19 years) with either severe traumatic brain injury (N = 176) or stroke (N = 25) signal data consisting of FV, ABP and (invasively assessed) ICP was used to validate nICP results. Modifications of a basic linear nICP model were made by means of a method called Fuzzy Pattern Classification which allowed an individual model adaptation in heterogeneous patient groups. In a second approach Fuzzy Pattern Classification was used for a pre-selection of the best fitting linear model. The results of these modified methods were compared to the former results of nICP assessment. Results: Two different linear models which were using different TCD characteristics for nICP calculation were evaluated. The models showed mean absolute differences between ICP and nICP (DICP) of 6.41 ± 5.74 mm Hg (median = 4.92 mm Hg) and 6.39 ± 5.76 mm Hg (median = 5.04 mm Hg). The Fuzzy Pattern approach of individual model adaptation resulted in a DICP of 6.54 ± 5.84 mm Hg (median = 5.29 mm Hg). The three results did not differ significantly (P > 0.05). If Fuzzy Pattern Classification was used to control application of linear procedures by selecting the best fit procedure the DICP could be reduced to 6.21 ± 5.50 mm Hg (median = 4.83 mm Hg) (P < 0.001). Conclusions: Although advanced methods of data analysis were used only minor improvements of nICP assessment accuracy could be achieved. With regard to the underlying data only low potential seems to be left for further improvement. Therefore, realisation of this method should be considered now.
Molecular Imaging and Biology | 2015
Dale L. Bailey; Gerald Antoch; Peter Bartenstein; Henryk Barthel; Ambros J. Beer; Sotirios Bisdas; D. A. Bluemke; Ronald Boellaard; C. D. Claussen; Christiane Franzius; Marcus Hacker; H. Hricak; C. la Fougère; Brigitte Gückel; Stephan G. Nekolla; Bernd J. Pichler; Sandra Purz; Harald H. Quick; Osama Sabri; Bernhard Sattler; Jürgen F. Schäfer; Holger Schmidt; J. van den Hoff; S. Voss; Wolfgang A. Weber; Thomas Beyer
Radiologe | 2016
Sergios Gatidis; Brigitte Gückel; C. la Fougère; J. Schmitt; Jürgen F. Schäfer
Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren | 2017
Susann-Cathrin Olthof; Patrick Krumm; J Jenes; Theodoros Xenitidis; Konstantin Nikolaou; C. la Fougère; Christina Pfannenberg; Nina F. Schwenzer